Metycor

Active substance

 Metyparone

Holder

 Laboratoires HRA Pharma

Status

Running

Indication

Endogenous Cushing’s syndrome in patients who have completed the study extension period of the PROMPT clinical trial with metyrapone

Public documents

Approbation

Information for the patient

Informed consent

Last update

18/05/2016
Last updated on 13/04/2021